2Verhoef P, Kok FJ, Kluijtmam LA, et al. The 677C-T mutation in the methylenetetrahydrofolate reductasc gene: associations with plasma total homocysteine levels and risk of coronary atherosclerotic disease. Atherosclerosis, 1997, 132: 105-113.
3Woo KS, Chook P, Lolin YI, ct ul. Folic acid improves arterial endotheliul function in adults with hyperhomocystinemia. J Am Coll Cardiol,1999, 34: 2002-2006.
4Woo KS, Chook P, Lolin YI, et al. Hyperhomocyst (e) inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation,1997, 96: 2542-2544.
5Woo KS, Qiao M, Chook P, et al. Homocysteine, endothelial dysfunction, and coron aryartery disease: emerging strategy for secondary prevention. J Card Stag, 2002, 17: 432-435.
6Woo KS, Chook P, Young RP, et al. New risk factors for coronary heart disease in Asia. IntJ Cardiol, 1997, 62: 39-42.
7Refsum H, Ueland PM, Nygard O, et al. Homocysteine and cardiovascular disease. Annu Rev Med, 1998, 49: 31-62.
8Woo KS, Chook P, Chart LL, et al. Long-term improvement in homocysteine levels and arterial endothelial function after 1-year folic acid supplementation. Am J Med, 2002, 112: 535-539.
9Graham IM, Da]y LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project.JAMA, 1997, 277: 1775-1781.
